Table 3.
Responses (clinical and MRD) by subgroups in evaluable patients
| Group | Response after induction | MRD response after induction | ||
|---|---|---|---|---|
| CR | PR | MRD negative | MRD positive | |
| All* | 20/40 (50%) | 20/40 (50%) | 22/39 (56%) | 17/39 (44%) |
| Age > 65 | 15/22 (68%) | 7/22 (32%) | 17/22 (77%) | 5/22 (23%) |
| FISH cytogenetics (hierarchical risk) | ||||
| Del(13q) | 11/18 (61%) | 7/18 (39%) | 8/17 (47%) | 9/17 (53%) |
| Trisomy 12 | 3/7 (43%) | 4/7 (57%) | 5/7 (71%) | 2/7 (29%) |
| Del(11q) | 3/9 (33%) | 6/9 (67%) | 5/9 (56%) | 4/9 (44%) |
| Del(17p) | 1/2 (50%) | 1/2 (50%) | 1/2 (50%) | 1/2 (50%) |
| No cytogenetic abnormalities | 2/4 (50%) | 2/4 (50%) | 3/4 (75%) | 1/4 (25%) |
| High-risk gene mutations | ||||
| ATM | 11/19 (58%) | 8/19 (42%) | 10/19 (53%) | 9/19 (47%) |
| BIRC3 | 1/2 (50%) | 1/2 (50%) | 2/2 (100%) | 0/2 (0%) |
| NFKBIE | 2/4 (50%) | 2/4 (50%) | 1/4 (25%) | 3/4 (75%) |
| NOTCH1 | 6/11 (55%) | 5/11 (45%) | 8/11 (73%) | 3/11 (27%) |
| SF3B1 | 3/3 (100%) | 0/3 (0%) | 3/3 (100%) | 0/3 (0%) |
| TP53 | 1/2 (50%) | 1/2 (50%) | 1/2 (50%) | 1/2 (50%) |
| ZNF292 | 4/6 (67%) | 2/6 (33%) | 1/6 (17%) | 5/6 (83%) |
| Unmutated IgVH | 11/17 (65%) | 6/17 (35%) | 10/17 (59%) | 7/17 (41%) |
*Forty patients evaluable for response; 39 patients with central MRD assessment; 75% of CRs were MRD negative